Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients

Cancer

Volumn 117, Issue 3, 2011, Pages 648-655

  Krishna, Somashekar G ^a   Zhao, Weizhi ^b   Grazziutti, Monica L ^b   Sanathkumar, Naveen ^b   Barlogie, Bart ^b   Anaissie, Elias J ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

chemotherapy and stem cell transplantation; gastrointestinal toxicity; lower alimentary tract mucositis; mucositis; neutropenic enterocolitis; typhlitis

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; SERUM ALBUMIN; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BODY SURFACE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COLITIS; CONFIDENCE INTERVAL; CREATININE CLEARANCE; DEATH; DRUG DOSE REDUCTION; DRUG MEGADOSE; ENTERITIS; FEMALE; HUMAN; INCIDENCE; INTESTINE MUCOSA; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; MYELOMA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY SURFACE AREA; COLITIS; ENTERITIS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; KIDNEY; MALE; MELPHALAN; MIDDLE AGED; MUCOSITIS; MULTIPLE MYELOMA; RISK FACTORS;

EID: 79251512966     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25633     Document Type: Article

References (47)

1. Khan SA, Wingard JR., Infection and mucosal injury in cancer treatment. J Natl Cancer Inst Monogr. 2001;(29): 31-36.
2. Bow EJ, Loewen R, Cheang MS, Shore TB, Rubinger M, Schacter B., Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol. 1997; 15: 2254-2261.
3. Davila ML., Neutropenic enterocolitis. Curr Opin Gastroenterol. 2006; 22: 44-47.
4. Ullery BW, Pieracci FM, Rodney JR, Barie PS., Neutropenic enterocolitis. Surg Infect (Larchmt). 2009; 10: 307-314.
5. Gorschluter M, Mey U, Strehl J, et al. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Haematol. 2005; 75: 1-13.
6. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007; 138: 176-185.
7. Grazziutti ML, Dong L, Miceli MH, etal. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant. 2006; 38: 501-506.
8. Yerly S, Perrin L, Van Delden C, et al. Cytomegalovirus quantification in plasma by an automated real-time PCR assay. J Clin Virol. 2007; 38: 298-303.
9. Janka J, O'Grady NP., Clostridium difficile infection: current perspectives. Curr Opin Crit Care. 2009; 15: 149-153.
10. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Published August 9, 2006. Available at:. Accessed on September 2, 2007.
11. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999; 341: 1565-1571.
12. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004; 351: 2590-2598.
13. Johansson JE, Ekman T., Gastro-intestinal toxicity related to bone marrow transplantation: disruption of the intestinal barrier precedes clinical findings. Bone Marrow Transplant. 1997; 19: 921-925.
14. Blijlevens NM, Donnelly JP, De Pauw BE., Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant. 2000; 25: 1269-1278.
15. Nath CE, Shaw PJ, Trotman J, Zeng L., Pharmacokinetics of melphalan in myeloma patients undergoing an autograft. Bone Marrow Transplant. 2007; 40: 707-708.
16. Kuhne A, Sezer O, Heider U, et al. Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects. Clin Pharmacol Ther. 2008; 83: 749-757.
17. Blijlevens NM., Cytotoxic treatment-induced gastrointestinal symptoms. Curr Opin Support Palliat Care. 2007; 1: 16-22.
18. Costa LJ, Micallef IN, Inwards DJ, et al. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. Br J Haematol. 2008; 143: 268-273.
19. Vokurka S, Steinerova K, Karas M, Koza V., Characteristics and risk factors of oral mucositis after allogeneic stem cell transplantation with FLU/MEL conditioning regimen in context with BU/CY2. Bone Marrow Transplant. 2009; 44: 601-615.
20. Wellcome G., Alkeran (Melphalan Hydrochloride) for Injection Prescribing Information. Research Triangle Park, NC: GlaxoSmithKline; 1998.
21. Kergueris MF, Milpied N, Moreau P, Harousseau JL, Larousse C., Pharmacokinetics of high-dose melphalan in adults: influence of renal function. Anticancer Res. 1994; 14: 2379-2382.
22. Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001; 114: 822-829.
23. Vigneau C, Ardiet C, Bret M, et al. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure. J Nephrol. 2002; 15: 684-689.
24. Kragh-Hansen U, Chuang VT, Otagiri M., Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull. 2002; 25: 695-704.
25. Dasgupta A., Clinical utility of free drug monitoring. Clin Chem Lab Med. 2002; 40: 986-993.
26. Product Information: Vepesid(R), Etopside. Evansville, IN: Bristol Laboratories; 1985.
27. Product Information: Adriamycin, Doxorubicin HCl. Bedford, OH: Bedford Laboratories; 2002.
28. Prescribing Information. Cambridge, MA: Millennium Pharmaceuticals, Inc, Rev 9. June 2008.
29. Product Information: Cisplatin USP Injection, Cisplatin USP Injection. Irvine, CA: SicorPharmaceuticals; 2003.
30. Product Information: Cytoxan(R), Cyclophosphamide. Evansville, IN: Bristol-Myers Oncology Division; 1990.
31. McCarville MB, Adelman CS, Li C, et al. Typhlitis in childhood cancer. Cancer. 2005; 104: 380-387.
32. Cartoni C, Dragoni F, Micozzi A, et al. Neutropenic enterocolitis in patients with acute leukemia: prognostic significance of bowel wall thickening detected by ultrasonography. J Clin Oncol. 2001; 19: 756-761.
33. Dietrich CF, Hermann S, Klein S, Braden B., Sonographic signs of neutropenic enterocolitis. World J Gastroenterol. 2006; 12: 1397-1402.
34. Kirkpatrick ID, Greenberg HM., Gastrointestinal complications in the neutropenic patient: characterization and differentiation with abdominal CT. Radiology. 2003; 226: 668-674.
35. Mullassery D, Bader A, Battersby AJ, et al. Diagnosis, incidence, and outcomes of suspected typhlitis in oncology patientsâexperience in a tertiary pediatric surgical center in the United Kingdom. J Pediatr Surg. 2009; 44: 381-385.
36. Khoury NJ, Kanj V, Abboud M, Muwakkit S, Birjawi GA, Haddad MC., Abdominal complications of chemotherapy in pediatric malignancies: imaging findings. Clin Imaging. 2009; 33: 253-260.
37. Davila M, Bresalier RS., Gastrointestinal complications of oncologic therapy. Nat Clin Pract Gastroenterol Hepatol. 2008; 5: 682-696.
38. Wade DS, Nava HR, Douglass HO Jr., Neutropenic enterocolitis. Clinical diagnosis and treatment. Cancer. 1992; 69: 17-23.
39. Gorschluter M, Marklein G, Hofling K, et al. Abdominal infections in patients with acute leukaemia: a prospective study applying ultrasonography and microbiology. Br J Haematol. 2002; 117: 351-358.
40. Gorschluter M, Glasmacher A, Hahn C, et al. Severe abdominal infections in neutropenic patients. Cancer Invest. 2001; 19: 669-677.
41. Buyukasik Y, Ozcebe OI, Haznedaroglu IC, et al. Neutropenic enterocolitis in adult leukemias. Int J Hematol. 1997; 66: 47-55.
42. Cardona Zorrilla AF, Reveiz Herault L, Casasbuenas A, Aponte DM, Ramos PL,. Systematic review of case reports concerning adults suffering from neutropenic enterocolitis. Clin Transl Oncol. 2006; 8: 31-38.
43. Abreu MT., Harnessing the power of bacteria to protect the gut. N Engl J Med. 2008; 359: 756-759.
44. Gomez L, Martino R, Rolston KV., Neutropenic enterocolitis: spectrum of the disease and comparison of definite and possible cases. Clin Infect Dis. 1998; 27: 695-699.
45. O'Brien S, Kantarjian HM, Anaissie E, Dodd G, Bodey GP., Successful medical management of neutropenic enterocolitis in adults with acute leukemia. South Med J. 1987; 80: 1233-1235.
46. Sloas MM, Flynn PM, Kaste SC, Patrick CC., Typhlitis in children with cancer: a 30-year experience. Clin Infect Dis. 1993; 17: 484-490.
47. Trotti A, Colevas AD, Setser A, Basch E., Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007; 25: 5121-5127.